139 related articles for article (PubMed ID: 19671806)
1. Anti-cyclic citrullinated peptide antibody versus HAQ/MDHAQ: comparing apples and oranges?
Bykerk V
J Rheumatol; 2009 Aug; 36(8):1565-7. PubMed ID: 19671806
[No Abstract] [Full Text] [Related]
2. Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool?
Pincus T; Yazici Y; Bergman MJ
J Rheumatol; 2009 Aug; 36(8):1563-4. PubMed ID: 19671805
[No Abstract] [Full Text] [Related]
3. Diagnostic value of anticyclic citrullinated peptide antibody in rheumatoid arthritis.
Jansen TL; Bruyn GA
J Rheumatol; 2004 May; 31(5):1012-3; author reply 1013. PubMed ID: 15124273
[No Abstract] [Full Text] [Related]
4. Does a positive anti-CCP test identify a distinct arthritis entity?
Skogh T
Arthritis Res Ther; 2005; 7(6):230-2. PubMed ID: 16277697
[TBL] [Abstract][Full Text] [Related]
5. Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis?
Holers VM
Nat Clin Pract Rheumatol; 2006 Aug; 2(8):400-1. PubMed ID: 16932728
[No Abstract] [Full Text] [Related]
6. Anti-cyclic citrullinated peptide in preclinical rheumatoid arthritis. Food for thought.
Ménard HA
J Rheumatol; 2009 Apr; 36(4):663-4. PubMed ID: 19342718
[No Abstract] [Full Text] [Related]
7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
8. [Early diagnosis of rheumatoid arthritis with a test based upon a specific antigen: cyclic citrullinated peptide].
Jansen TL
Ned Tijdschr Geneeskd; 2003 Apr; 147(15):729-30; author reply 730-1. PubMed ID: 12722537
[No Abstract] [Full Text] [Related]
9. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor.
Bossuyt X; Coenen D; Fieuws S; Verschueren P; Westhovens R; Blanckaert N
Ann Rheum Dis; 2009 Feb; 68(2):287-9. PubMed ID: 19139208
[No Abstract] [Full Text] [Related]
10. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
Rodríguez-Mahou M; López-Longo FJ; Sánchez-Ramón S; Estecha A; García-Segovia A; Rodríguez-Molina JJ; Carreño L; Fernández-Cruz E
Arthritis Rheum; 2006 Aug; 55(4):657-61. PubMed ID: 16874789
[No Abstract] [Full Text] [Related]
11. Diagnostic value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
Mofidi M; Moghadam A
Saudi Med J; 2008 Aug; 29(8):1206-7. PubMed ID: 18690324
[No Abstract] [Full Text] [Related]
12. Anti-cyclic citrullinated peptide antibody determination in the synovial fluid of patients with rheumatoid arthritis: comment on the article by Caspi et al.
Spadaro A; Riccieri V; Scrivo R; Alessandri C; Valesini G
Arthritis Rheum; 2006 Aug; 55(4):681-2; author reply 682. PubMed ID: 16874773
[No Abstract] [Full Text] [Related]
13. Clinical significance of anti-citrullinated peptide antibody in Japanese patients with established rheumatoid arthritis.
Nakamura H; Kawakami A; Ida H; Origuchi T; Matsuoka N; Tsuboi M; Furuyama M; Mizokami A; Tsukada T; Nakashima M; Ejima E; Hamasaki K; Aoyagi K; Uetani M; Fukuda T; Honda S; Urayama S; Kawabe Y; Ueki Y; Mine M; Eguchi K
Scand J Rheumatol; 2005; 34(6):489-90. PubMed ID: 16393775
[No Abstract] [Full Text] [Related]
14. Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results?
Marchesoni A; Lurati A; Desiati F; Rossi V; Battafarano N
J Rheumatol; 2006 Feb; 33(2):435; author reply 436-7. PubMed ID: 16465678
[No Abstract] [Full Text] [Related]
15. Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis.
Jacobsen S; Garred P; Madsen HO; Heegaard NH; Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Ellingsen T; Smedegaard Andersen L; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Pødenphant J; Lindegaard H; Vestergaard A; Østergaard M; Hørslev-Petersen K
J Rheumatol; 2009 Apr; 36(4):731-5. PubMed ID: 19273450
[TBL] [Abstract][Full Text] [Related]
16. The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/ environment/immunity interactions.
Lee W; Weisman MH
J Rheumatol; 2006 Jul; 33(7):1216-8. PubMed ID: 16821260
[No Abstract] [Full Text] [Related]
17. Anti-CCP antibodies as an aid to prioritization of patients referred to the rheumatology clinic.
Madan A; Belshaw R; Grennan D
QJM; 2007 Nov; 100(11):737-8. PubMed ID: 17951317
[No Abstract] [Full Text] [Related]
18. Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion.
Bos WH; Nielen MM; Dijkmans BA; van Schaardenburg D
Ann Rheum Dis; 2008 Nov; 67(11):1642. PubMed ID: 18854513
[No Abstract] [Full Text] [Related]
19. Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
Kitahara K; Takagi K; Kusunoki Y; Nishio S; Nozaki T; Inomata H; Takei M; Sawada S; Kawai S
Ann Rheum Dis; 2008 Jul; 67(7):1059-60. PubMed ID: 18556455
[No Abstract] [Full Text] [Related]
20. Anti-citrullinated protein antibody response associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis.
Willemze A; Ioan-Facsinay A; El-Gabalawy H
J Rheumatol; 2008 Nov; 35(11):2282-4. PubMed ID: 19004060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
